Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 441, 23 (4 May 2006) | doi:10.1038/441023a; Published online 3 May 2006
In brief
The European Commission granted its first-ever approval to a generic biological drug — for Omnitrope, a copycat version of human growth hormone, made by the Sandoz unit of Swiss drug-maker Novartis. The landmark decision was made under a 2005 law that opens a route to market for biogenerics in Europe (see Nature 438, 154–155; 2005).
To read this story in full you will need to login or make a payment (see right).